The role of dopamine in obsessive-compulsive disorder: Preclinical and clinical evidence

Journal of Clinical Psychiatry

Volumn 65, Issue SUPPL. 14, 2004, Pages 11-17

  Denys, Damiaan ^a   Zohar, Joseph ^b   Westenberg, Herman G M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ANIMAL; ARTICLE; CLINICAL TRIAL; DISEASE MODEL; DRUG COMBINATION; HUMAN; OBSESSIVE COMPULSIVE DISORDER; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG THERAPY, COMBINATION; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 16544392764     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Barr LC, Goodman WK, Price LH, et al. The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. J Clin Psychiatry 1992;53(4, suppl):17-28
2. Pigott TA. OCD: where the serotonin selectivity story begins. J Clin Psychiatry 1996;57(suppl 6):11-20
3. Blier P, de Montigny C. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry 1998;44:313-323
4. Goodman WK, McDougle CJ, Price LH. The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder. Int Clin Psychopharmacol 1992;7(suppl 1): 35-38
5. McDougle CJ. Update on pharmacologic management of OCD: agents and augmentation. J Clin Psychiatry 1997;58(suppl 12):11-17
6. Goodman WK, McDougle CJ, Price LH, et al. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry 1990;51(8, suppl):36-43
7. Campbell KM, de Lecea L, Severynse DM, et al. OCD-like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons. J Neurosci 1999;19:5044-5053
8. Campbell KM, McGrath MJ, Burton FH. Behavioral effects of cocaine on a transgenic mouse model of cortical-limbic compulsion. Brain Res 1999;833:216-224
9. Campbell KM, McGrath MJ, Burton FH. Differential response of corticallimbic neuropotentiated compulsive mice to dopamine D1 and D2 receptor antagonists. Eur J Pharmacol 1999;371:103-111
10. McGrath MJ, Campbell KM, Parks CR, et al. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res 2000;877:23-30
11. Campbell KM, Veldman MB, McGrath MJ, et al. TS+OCD-like neuropotentiated mice are supersensitive to seizure induction. Neuroreport 2000;11:2335-2338
12. Einat H, Szechtman H. Perseveration without hyperlocomotion in a spontaneous alternation task in rats sensitized to the dopamine agonist quinpirole. Physiol Behav 1995;57:55-59
13. Szechtman H, Sulis W, Eilam D. Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci 1998;112:1475-1485
14. Ben Pazi A, Szechtman H, Eilam D. The morphogenesis of motor rituals in rats treated chronically with the dopamine agonist quinpirole. Behav Neurosci 2001;115:1301-1317
15. Szechtman H, Eckert MJ, Tse WS, et al. Compulsive checking behavior of quinpirole-sensitized rats as an animal model of obsessive-compulsive disorder (OCD): form and control. BMC Neurosci 2001;2:4
16. Sullivan RM, Talangbayan H, Einat H, et al. Effects of quinpirole on central dopamine systems in sensitized and non-sensitized rats. Neuroscience 1998;83:781-789
17. Joel D, Avisar A. Excessive lever pressing following post-training signal attenuation in rats: a possible animal model of obsessive compulsive disorder? Behav Brain Res 2001;123:77-87
18. Joel D, Doljansky J. Selective alleviation of compulsive lever-pressing in rats by D(1), but not D(2), blockade: possible implications for the involvement of D(1) receptors in obsessive-compulsive disorder. Neuropsychopharmacology 2003;28:77-85
19. Thoren P, Asberg M, Bertilsson L, et al. Clomipramine treatment of obsessive-compulsive disorder, 2: biochemical aspects. Arch Gen Psychiatry 1980;37:1289-1294
20. Benkelfat C, Mefford IN, Masters CF, et al. Plasma catecholamines and their metabolites in obsessive-compulsive disorder. Psychiatry Res 1991;37:321-331
21. Swedo SE, Leonard HL, Kruesi MJ, et al. Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49:29-36
22. Hollander E, Stein DJ, Saoud JB, et al. Effects of fenfluramine on plasma HVA in OCD [letter]. Psychiatry Res 1992;42:185-188
23. Zahn TP, Kruesi MJ, Swedo SE, et al. Autonomic activity in relation to cerebrospinal fluid neurochemistry in obsessive and disruptive children and adolescents. Psychophysiology 1996;33:731-739
24. Marazziti D, Hollander E, Lensi P, et al. Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder. Psychiatry Res 1992;42: 41-51
25. Little KY, Zhang L, Desmond T, et al. Striatal dopaminergic abnormalities in human cocaine users. Am J Psychiatry 1999;156:238-245
26. McDougle CJ, Goodman WK, Delgado PL, et al. Pathophysiology of obsessive-compulsive disorder [letter]. Am J Psychiatry 1989;146:1350-1351
27. Rosse RB, Fay-McCarthy M, Collins JP Jr, et al. The relationship between cocaine-induced paranoia and compulsive foraging: a preliminary report. Addiction 1994;89:1097-1104
28. Rosse RB, Fay-McCarthy M, Collins JP Jr, et al. Transient compulsive foraging behavior associated with crack cocaine use. Am J Psychiatry 1993;150:155-156
29. Koizumi HM. Obsessive-compulsive symptoms following stimulants. Biol Psychiatry 1985;20:1332-1333
30. Satel SL, McDougle CJ. Obsessions and compulsions associated with cocaine abuse [letter]. Am J Psychiatry 1991;148:947
31. Rosse RB, McCarthy MF, Alim TN, et al. Saccadic distractibility in cocaine dependent patients: a preliminary laboratory exploration of the cocaine-OCD hypothesis. Drug Alcohol Depend 1994;35:25-30
32. Lemus CZ, Robinson DG, Kronig M, et al. Behavioral responses to a dopaminergic challenge in obsessive-compulsive disorder. J Anxiety Disord 1991;5: 369-373
33. Kouris S. Methylphenidate-induced obsessive-compulsiveness [letter]. J Am Acad Child Adolesc Psychiatry 1998;37:135
34. Kotsopoulos S, Spivak M. Obsessive-compulsive symptoms secondary to methylphenidate treatment [letter]. Can J Psychiatry 2001;46:89
35. Frye PE, Arnold LE. Persistent amphetamine-induced compulsive rituals: response to pyridoxine(B6). Biol Psychiatry 1981;16:583-587
36. Iyo M, Sekine Y, Matsunaga T, et al. Methamphetamine-associated obsessional symptoms and effective risperidone treatment: a case report [letter]. J Clin Psychiatry 1999;60:337-338
37. Joffe RT, Swinson RP. Methylphenidate in primary obsessive-compulsive disorder. J Clin Psychopharmacol 1987;7:420-422
38. Joffe RT, Swinson RP, Levitt AJ. Acute psychostimulant challenge in primary obsessive-compulsive disorder. J Clin Psychopharmacol 1991;11:237-241
39. Insel TR, Hamilton JA, Guttmacher LB, et al. D-amphetamine in obsessive-compulsive disorder. Psychopharmacology (Berl) 1983;80:231-235
40. Pitchot W, Hansenne M, Moreno AG, et al. Growth hormone response to apomorphine in obsessive-compulsive disorder. J Psychiatry Neurosci 1996;21:343-345
41. Brambilla F, Bellodi L, Perna G, et al. Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation. Biol Psychiatry 1997;42:889-897
42. Brambilla F, Perna G, Bussi R, et al. Dopamine function in obsessive compulsive disorder: cortisol response to acute apomorphine stimulation. Psychoneuroendocrinology 2000;25:301-310
43. Longhurst JG, Carpenter LL, Epperson CN, et al. Effects of catecholamine depletion with AMPT (alpha-methyl-para-tyrosine) in obsessive-compulsive disorder. Biol Psychiatry 1999;46:573-576
44. Ceccherini-Nelli A, Guazzelli M. Treatment of refractory OCD with the dopamine agonist bromocriptine [letter]. J Clin Psychiatry 1994;55:415-416
45. Trethowan WH, Scott PA. Chlorpromazine in obsessive-compulsive and allied disorders. Lancet 1955;268:781-785
46. Hussain MZ, Ahad A. Treatment of obsessive-compulsive neurosis [letter]. Can Med Assoc J 1970;103:648
47. O'Regan JB. Treatment of obsessive-compulsive neurosis [letter]. Can Med Assoc J 1970;103:650-651
48. O'Regan JB. Treatment of obsessive-compulsive neurosis with haloperidol [letter]. Can Med Assoc J 1970;103:167-168
49. Altschuler M. Massive doses of trifluoperazine in the treatment of compulsive rituals [letter]. Am J Psychiatry 1962;119:367-368
50. Rivers-Bulkeley N, Hollender MH. Successful treatment of obsessive-compulsive disorder with loxapine [letter]. Am J Psychiatry 1982;139:1345-1346
51. McDougle CJ, Barr LC, Goodman WK, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 1995;152:1812-1814
52. Lykouras L, Alevizos B, Michalopoulou P, et al. Obsessive-compulsive symptoms induced by atypical antipsychotics: a review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:333-346
53. McDougle CJ, Goodman WK, Price LH, et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990;147:652-654
54. Shapira NA, Ward HE, Mandoki M, et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 2004;55:553-555
55. Sevincok L, Topuz A. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder. J Clin Psychopharmacol 2003;23:448-450
56. Metin O, Yazici K, Tot S, et al. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol 2003;18:463-467
57. Ramasubbu R. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent [letter]. Arch Gen Psychiatry 2002;59:472-473
58. Zhang W, Bymaster FP. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology (Berl) 1999;141:267-278
59. Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000;23:250-262
60. Denys D, Klompmakers AA, Westenberg HG. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berl). In press
61. Sawle GV, Hymas NF, Lees AJ, et al. Obsessional slowness: functional studies with positron emission tomography. Brain 1991;114(pt 5):2191-2202
62. van der Wee N, Stevens H, Hardeman H, et al. Enhanced densities of dopamine but not of serotonin transporters in psychotropic-naïve patients with obsessive-compulsive disorder [abstract]. J Nucl Med 2001;42:238P
63. Kim CH, Koo MS, Cheon KA, et al. Dopamine transporter density of basal ganglia assessed with [(123)I]IPT SPET in obsessive-compulsive disorder. Eur J Nucl Med Mol Imaging 2003;30:1637-1643
64. Pogarell O, Hamann C, Popperl G, et al. Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biol Psychiatry 2003;54:1406-1413
65. Denys D, van der Wee N, Janssen J, et al. Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol Psychiatry 2004;55:1041-1045
66. Frisch A, Michaelovsky E, Rockah R, et al. Association between obsessivecompulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways. Eur Neuropsychopharmacol 2000;10:205-209
67. Hemmings SM, Kinnear CJ, Niehaus DJ, et al. Investigating the role of dopaminergic and serotonergic candidate genes in obsessive-compulsive disorder. Eur Neuropsychopharmacol 2003;13:93-98
68. Catalano M, Sciuto G, Di Bella D, et al. Lack of association between obsessive-compulsive disorder and the dopamine D3 receptor gene: some preliminary considerations. Am J Med Genet 1994;54:253-255
69. Nicolini H, Cruz C, Camarena B, et al. DRD2, DRD3 and 5HT2A receptor genes polymorphisms in obsessive-compulsive disorder. Mol Psychiatry 1996;1:461-465
70. Denys D, van Nieuwerburgh P, Deforce D, et al. An association between dopamine system genes and obsessive-compulsive disorder. In: Denys D. On Certainty. Utrecht, The Netherlands: UMC Utrecht; 2004:163-171
71. Novelli E, Nobile M, Diaferia G, et al. A molecular investigation suggests no relationship between obsessive-compulsive disorder and the dopamine D2 receptor. Neuropsychobiology 1994;29:61-63
72. Billett EA, Richter MA, Sam F, et al. Investigation of dopamine system genes in obsessive-compulsive disorder. Psychiatr Genet 1998;8:163-169
73. Cruz C, Camarena B, King N, et al. Increased prevalence of the seven-repeat variant of the dopamine D4 receptor gene in patients with obsessive-compulsive disorder with tics. Neurosci Lett 1997;231:1-4
74. Millet B, Chabane N, Delorme R, et al. Association between the dopamine receptor D4 (DRD4) gene and obsessive-compulsive disorder. Am J Med Genet 2003;116:55-59
75. Di Bella D, Catalano M, Cichon S, et al. Association study of a null mutation in the dopamine D4 receptor gene in Italian patients with obsessive-compulsive disorder, bipolar mood disorder and schizophrenia. Psychiatr Genet 1996;6:119-121
76. Karayiorgou M, Altemus M, Galke BL, et al. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci U S A 1997;94:4572-4575
77. Karayiorgou M, Sobin C, Blundell ML, et al. Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder. Biol Psychiatry 1999;45:1178-1189
78. Alsobrook JP, Zohar AH, Leboyer M, et al. Association between the COMT locus and obsessive-compulsive disorder in females but not males. Am J Med Genet 2002;114:116-120
79. Niehaus DJ, Kinnear CJ, Corfield VA, et al. Association between a catechol-o-methyltransferase polymorphism and obsessive-compulsive disorder in the Afrikaner population. J Affect Disord 2001;65:61-65
80. Schindler KM, Richter MA, Kennedy JL, et al. Association between homozygosity at the COMT gene locus and obsessive compulsive disorder. Am J Med Genet 2000;96:721-724
81. Ohara K, Nagai M, Suzuki Y, et al. No association between anxiety disorders and catechol-O-methyltransferase polymorphism. Psychiatry Res 1998;80:145-148
82. Erdal ME, Tot S, Yazici K, et al. Lack of association of catechol-O-methyltransferase gene polymorphism in obsessive-compulsive disorder. Depress Anxiety 2003;18:41-45
83. Azzam A, Mathews C, Reus V. A meta-analysis of the association between the catecholamine-O-methyl-transferase gene and obsessive-compulsive disorder. Am J Med Genet 2002;114:834-835
84. Saxena S, Brody AL, Schwartz JM, et al. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry Suppl 1998:26-37
85. Jenike MA, Baer L, Minichiello WE. Obsessive-Compulsive Disorders. Practical Management, 3rd Edition. St. Louis, Mo: Mosby; 1998
86. LeDoux JE. The Emotional Brain. New York, NY: Simon & Schuster; 1996
87. Rosenkranz JA, Grace AA. Dopamine-mediated modulation of odourevoked amygdala potentials during pavlovian conditioning. Nature 2002;417:282-287
88. Holden C. 'Behavioral' addictions: do they exist? Science 2001;294:980-982
89. Fiorillo CD, Tobler PN, Schultz W. Discrete coding of reward probability and uncertainty by dopamine neurons. Science 2003;299:1898-1902
90. McDougle CJ, Fleischmann RL, Epperson CN, et al. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 1995;56:526-528
91. Saxena S, Wang D, Bystritsky A, et al. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-306
92. Stein DJ, Bouwer C, Hawkridge S, et al. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997;58:119-122
93. Pfanner C, Marazziti D, Dell'Osso L, et al. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol 2000;15:297-301
94. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794-801
95. Baxter LR, Li X, Jackson WT, et al. Adjunctive risperidone in the treatment of SSRI-refractory obsessive compulsive disorder. Presented at the annual meeting of the Society of Biological Psychiatry; May 16-18, 2002; Philadelphia, Pa
96. Hollander E, Rossi NB, Sood E, et al. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2003;6:397-401
97. Weiss EL, Potenza MN, McDougle CJ, et al. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 1999;60:524-527
98. Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2000;61:514-517
99. Bogetto F, Bellino S, Vaschetto P, et al. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 2000;96:91-98
100. Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry 2001;46:356-358
101. Crocq MA, Leclercq P, Guillon MS, et al. Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment. Eur Psychiatry 2002;17:296-297
102. D'Amico G, Cedro C, Muscatello MR, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:619-623
103. Bystritsky A, Ackerman DL, Rosen RM, et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 2004;65:565-568
104. Mohr N, Vythilingum B, Emsley RA, et al. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol 2002;17:37-40
105. Atmaca M, Kuloglu M, Tezcan E, et al. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002;17:115-119
106. Denys D, van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry 2002;63:700-703
107. Kinnear C, Niehaus DJ, Seedat S, et al. Obsessive-compulsive disorder and a novel polymorphism adjacent to the oestrogen response element (ERE 6) upstream from the COMT gene. Psychiatr Genet 2001;11:85-87
108. Meira-Lima I, Shavitt RG, Miguita K, et al. Association analysis of the catechol-o-methyltransferase (COMT), serotonin transporter (5-HTT) and serotonin 2A receptor (5HT2A) gene polymorphisms with obsessive-compulsive disorder. Genes Brain Behav 2004;3:75-79
109. Denys D, De Geus F, van Megen HJ, et al. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004;65:1040-1048